MDGL Madrigal Pharmaceuticals (MDGL) Q1 FY26 earnings call
Madrigal Pharmaceuticals reported a strong start to FY26, with Rezdiffra achieving blockbuster status and demonstrating significant patient growth. The company is strategically expanding its pipeline through targeted business development, aiming to solidify its leadership in the rapidly growing MASH market. While profitability is not expected in the current fiscal year due to investments, management anticipates it will be inevitable beyond 2026.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MDGL operating KPIs by quarter
| KPI | This call Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|
| Patients Rezdiffra | 42.25K+We ended the first quarter with more than 42,250 active patients on Rezdiffra.Source: earnings call transcript | 49K+That's why we've steadily added patients ending the second quarter with more than 49,000 active patients on Rezdiffra, more than double a year ago.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.